Clinicopathological and Preclinical Patient-Derived Model Studies Define High Expression of NRN1 as a Diagnostic and Therapeutic Target for Clear Cell Renal Cell Carcinoma

Shuhei Kamada1,2†, Kazuhiro Ikeda1†, Takashi Suzuki3, Wataru Sato1, Sachi Kitayama1, Satoru Kawakami4, Tomohiko Ichikawa2, Kuniko Horie1* and Satoshi Inoue1,5*

1 Division of Systems Medicine & Gene Therapy, Saitama Medical University, Saitama, Japan, 2 Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan, 3 Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Miyagi, Japan, 4 Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 5 Department of Systems Aging Science and Medicine, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan

Background: Acquired therapeutic resistance and metastasis/recurrence remain significant challenge in advance renal cell carcinoma (RCC), thus the establishment of patient-derived cancer models may provide a clue to assess the problem. We recently characterized that neuritogenesis-related protein neuritin 1 (NRN1) functions as an oncogene in testicular germ cell tumor. This study aims to elucidate the role of NRN1 in RCC.

Methods: NRN1 expression in clinical RCC specimens was analyzed based on immunohistochemistry. NRN1-associated genes in RCC were screened by the RNA-sequencing dataset from The Cancer Genome Atlas (TCGA). RCC patient-derived cancer cell (RCC-PDC) spheroid cultures were established and their viabilities were evaluated under the condition of gene silencing/overexpression. The therapeutic effect of NRN1-specific siRNA was evaluated in RCC-PDC xenograft models.

Results: NRN1 immunoreactivity was positively associated with shorter overall survival in RCC patients. In TCGA RCC RNA-sequencing dataset, C-X-C chemokine receptor type 4 (CXCR4), a prognostic and stemness-related factor in RCC, is a gene whose expression is substantially correlated with NRN1 expression. Gain- and loss-of-function studies in RCC-PDC spheroid cultures revealed that NRN1 significantly promotes cell viability along with the upregulation of CXCR4. The NRN1-specific siRNA injection significantly suppressed the proliferation of RCC-PDC-derived xenograft tumors, in which CXCR4 expression is significantly repressed.
INTRODUCTION

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, with >400,000 new cases diagnosed worldwide in 2018 (1, 2). Patients with resectable RCC have relatively good prognosis with a 5-year survival rate of >90%, whereas those with recurrent or metastatic RCC still have a poor prognosis with a 5-year survival rate of 10–20% (3). New therapeutic strategies including immune checkpoint inhibitors improve prognosis of RCC patients nowadays; yet not all patients respond to these therapies and positive responses are usually achieved in a minority of cases (4, 5). Thus, more effective RCC strategy to all RCC patients remains to be developed.

Recent advance in cancer research technology has provided useful platforms to dissect potential diagnostic and therapeutic targets. In particular, patient-derived cancer models are applied to preclinical tests for drug screening. We have established patient-derived cancer cell (PDC) spheroid culture systems. The three-dimensional culture technology is useful to preferentially enrich cancer stem-like cells (CSCs) with self-renewal, a cell population often responsible for tumor recurrence/metastasis and therapeutic resistance (6–11). PDC system also has a particular advantage that can be applied to establish in vivo PDC-derived xenograft (PDCX) models (12–14).

We recently demonstrated that neuritogenesis-related protein neuritin 1 (NRN1) can be a potential therapeutic target in testicular germ cell tumor (TGCT) under the regulation by HIF1α (12). Because NRN1 expression is positively associated with the proliferation of patient-derived TGCT spheroid cultures with cancer stemness features, we here extend our question whether NRN1 contributes to the proliferation of RCC cells, particularly in clear cell carcinoma where HIF1α signaling is predominantly activated due to mutational inactivation of VHL. While NRN1 is a glycosylphosphatidylinositol-anchored protein and involved in neuritogenesis (15), NRN1 expression is hypoxia-inducible and its high mRNA expression was observed in a restricted number of tumor cells around perinecrotic regions of a case of conventional RCC (16).

In the present study, based on our findings and previous literature, we aimed to characterize whether NRN1 contributes to RCC biology, particularly to cancer stemness in ccRCC. NRN1 plays a tumor-promoting role in RCC. PDC/PDCX-based and pathological analyses of RCC uncovered that NRN1 and its co-expressing molecule CXCR4 are positively associated with RCC patient prognosis and their silencing substantially suppresses PDC viability and PDCX tumor growth. Our findings will provide a potential basis for the development of alternative diagnostic and therapeutic options for patients with RCC.

Conclusion: NRN1 can be a potential diagnostic and therapeutic target in RCC as analyzed by preclinical patient-derived cancer models and clinicopathological studies.

Keywords: renal cell carcinoma, patient-derived cancer cell (PDC), patient-derived xenograft, cancer stem-like cell, cancer stemness, spheroid, neuritin 1, C-X-C chemokine receptor type 4

MATERIALS AND METHODS

Clinical Data Collection and Patient Selection

A cohort of 100 patients with clear cell RCC (ccRCC) diagnosed at the Saitama Medical Center between 2008 and 2019 were retrospectively analyzed. We evaluated the overall survival of the patients from the time of their first visit. Patient characteristics are shown in Table 1. Patients who did not agree to participate in the study were excluded. The clinical parameters whose values were not available were excluded from the statistical analysis to compare the patient characteristics. Pathological findings were classified according to the Japanese General Rules for Clinical and Pathological Studies on Renal Cell Carcinoma (17). The Institutional Review Board of the Saitama Medical Center, Saitama Medical University, approved the clinical protocols (No. 117 and No. 2308).

The Cancer Genome Atlas (TCGA) RCC dataset retrieved from The Human Protein Atlas (https://www.proteinatlas.org/) was used for prognostic analysis for NRN1 and CXCR4 mRNA. For co-expression analysis, mRNA expression data in TCGA ccRCC RNA-sequencing (RNA-seq) dataset were retrieved from cBioPortal (https://www.cbioportal.org/). Gene ontology (GO) analysis was performed using The Database for Annotation, Visualization and Integrated Discovery (DAVID) (https://david.ncifcrf.gov/tools.jsp).

Patient-Derived RCC Spheroid Cultures and Cell Lines

Patient-derived ccRCC spheroid cultures were established from primary tumors of patients with RCC after obtaining informed consent at the Saitama Medical Center. Tumor samples were processed and cultured as three-dimensional spheroids as described previously (13). Characteristics of the patient PDCs are summarized in Supplementary Table 1. The Ethics Committee of the Saitama Medical Center, Saitama Medical University, approved all procedures (No. 1363-IV).

cDNA Synthesis and Quantitative Reverse-Transcription Polymerase Chain Reaction

RNA extraction, cDNA synthesis, and qRT-PCR were performed as described previously (13). β-Actin (ACTB) was used as the internal control. All qRT-PCR primers used in this study are listed in Supplementary Table 2.

siRNA, Expression Vector, and Transfection

siRNAs targeting NRN1 (siNRN1 #1 and #2) and control siRNA (sicontrol) were purchased from RNAi Inc. and transfected into...
PDCs with RNAiMAX reagent (Thermo Fisher Scientific) according to the manufacturer’s instructions. The siRNA sequences used are shown in Supplementary Table 3. Flag-tagged NRN1 cDNA was subcloned into pcDNA3 (Invitrogen) and transfected into PDCs with Lipofectamine 3000 reagent (Thermo Fisher Scientific) according to the manufacturer’s instructions.

**Cell Viability Assay for Spheroid Cultures**

Cell viability was assessed using the CellTiter-Glo 3D Assay (Promega) on day 3 after plating and transfection.

**Western Blotting**

RCC-PDC1 cells transfected with siRNAs or expression vectors were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate, 1 mM PMSF, 1 μg/mL aprotinin) and the plasma membrane fraction was purified by centrifugation at 19,100g for 20 min at 4°C. Proteins were separated with SDS-PAGE and blotted on PVDF membrane, followed by reactions with anti-CXCR4 antibody (GTX22074, GeneTex) or anti-β-actin antibody (AC-74, SigmaAldrich) for loading control.

**Immunohistochemistry**

Formalin-fixed tissues and PDCs resuspended in iPGel (Genostaff) were embedded in paraffin and sectioned as previously described (13). A Histofine kit (Nichirei) based on the streptavidin-biotin amplification method was used for immunohistochemical analyses of NRN1 (anti-NRN1 antibody PRS4101, Sigma-Aldrich) and CXCR4 (anti-CXCR4 antibody GTX22074, GeneTex). Specialized pathologists evaluated the

---

**TABLE 1 |** Association between NRN1 immunoreactivity and clinicopathological factors in 100 clear cell RCCs.

| NRN1 immunoreactivity | High (n = 21) | Low (n = 79) | P value |
|------------------------|---------------|--------------|---------|
| Age (years, median 67) |               |              |         |
| ≥ 67                   | 13            | 41           | 0.47    |
| < 67                   | 8             | 38           |         |
| Gender                 |               |              |         |
| Male                   | 15            | 54           |         |
| Female                 | 6             | 25           |         |
| Stage                  |               |              |         |
| I                      | 10            | 43           |         |
| II                     | 0             | 11           |         |
| III                    | 3             | 11           |         |
| IV                     | 8             | 14           | 0.10    |
| Pathological T factor (pT) |           |              |         |
| pT1-2                  | 14            | 62           | 0.26    |
| pT3-4                  | 7             | 17           |         |
| Lymph node metastasis  |               |              |         |
| Positive               | 3             | 2            | 0.061   |
| Negative               | 18            | 77           |         |
| Distant metastasis     |               |              |         |
| Positive               | 8             | 13           | 0.072   |
| Negative               | 14            | 65           |         |
| Grade (Furhman)        |               |              |         |
| 1-2                    | 14            | 54           |         |
| 3-4                    | 7             | 25           | 1.0     |
| IMDC risk group classification |           |              | 0.0027  |
| Favorable              | 6             | 35           |         |
| Intermediate           | 10            | 43           |         |
| Poor                   | 5             | 1            |         |
| Hb (g dl⁻¹, median M: 13.2, F: 12.2)| |              |         |
| ≥ LLN a                | 10            | 44           | 0.62    |
| < LLN                  | 11            | 35           |         |
| Corrected serum calcium b (mg dl⁻¹, median 9.3) | | | |
| ≥ 10                   | 9             | 11           | 0.011   |
| < 10                   | 12            | 68           |         |
| LDH (g dl⁻¹, median 184)| |              |         |
| ≥ 1.5 × ULN c          | 1             | 1            | 0.38    |
| < 1.5 × ULN            | 20            | 78           |         |
| CRP (mg dl⁻¹, median 0.20) | | | |
| ≥ 0.20                 | 17            | 41           | 0.024   |
| < 0.20                 | 4             | 38           |         |

*P value < 0.05 and 0.05 ≤ P value < 0.10 were significant (in bold) and borderline significant (in italics), respectively.

aLLN of Hb are 13.5 and 11.3 g/dL for male and female, respectively.

bCorrected serum calcium (mg dl⁻¹) = measured total calcium (mg dl⁻¹) + 0.8 (4.0 - serum albumin (g dl⁻¹)).

cULN of LDH is 245 U l⁻¹.

IMDC, International Metastatic RCC Database Consortium; Hb, hemoglobin; LLN, lower limit of normal; ULN, upper limit of normal; LDH, lactate dehydrogenase; CRP, C-reactive protein.
percentage of immune-positive tumor cells. Immunoreactivity of NRN1 and CXCR4 was detected in the cytoplasm of RCC cells and considered high when the cases had more than 10% of the positive carcinoma cells.

**Animal Experiments**

All animal experiments were approved by the Animal Care and Use Committee of Saitama Medical University, and carried out in accordance with the Guidelines and Regulations for the Care and Use of Experimental Animals of Saitama Medical University. For the xenograft model, 1.5 × 10^6 RCC-PDCs were suspended in 150 μl of medium containing 50% Matrigel (BD Biosciences, San Diego, CA) and subcutaneously injected into the flank of male NOG mice (In-Vivo Science, Washington, DC) or male nude mice (BALB/cAjl-nu/nu) as described previously (13). The RCC-PDC1-derived tumor generated in nude mice was cut into 2-mm cubes and inoculated into the flanks of 8-week-old nude mice. The tumors were measured in two-dimension using micrometer calipers, and the tumor volume was estimated according to the formula: 0.5 × ((smallest diameter)² × (longest diameter)). When the tumor volume exceeded 150 mm³, mice were randomly assigned to one of two groups: siNRN1 #1- and siControl-administered groups (n = 5, each group). siRNA duplexes (5 μg) were mixed with 4 μl GeneSilencer reagent (Gene Therapy System, San Diego, CA), dissolved in 50 μl Dulbecco’s modified Eagle’s medium, and then directly injected into the tumors twice weekly. The results were represented as mean ± SD. Student’s t-test was used for statistical analysis. At the end point of the experiment (3 weeks after siRNA administration), the tumors were dissected from the mice.

**Statistical Analysis**

Clinical data were analyzed using the log-rank test for the Kaplan-Meier method and Fisher’s exact test for patient characteristics. Experimental data were analyzed using a two-sided Student’s t-test for pairwise comparisons. For multiple comparisons, a two-way ANOVA test was used. Univariate and multivariate analyses were performed using the Cox proportional hazard model. Overall survival curves were generated using the Kaplan-Meier method, and statistical significance was determined using the log-rank test. Statistical computations were carried out using EZR software (version 1.54) (18).

**RESULTS**

**NRN1 Expression is Correlated With Poor Prognosis in Patients With RCC**

To assess the clinical significance of NRN1 in RCC, we performed immunohistochemical (IHC) analysis of NRN1 in ccRCC tumor samples obtained from distinct patients. We determined that 21 of 100 tumor tissues exhibited high NRN1 IHC staining in the cytoplasm of cancer cells (Figure 1A). Kaplan-Meier analysis of the 100 cases showed that the patients with high NRN1 IHC staining showed significant shorter overall survival rate than those with low NRN1 IHC staining (P = 3.1e-4) (Figure 1B). In clinicopathological analysis, NRN1 immunoreactivity was significantly correlated with corrected serum calcium (P = 0.011) and C-reactive protein (CRP) (P = 0.024) (Table 1). NRN1 immunoreactivity was also associated with the International Metastatic RCC Database Consortium (IMDC) risk group classification, which is used to stratify patients with metastatic RCC (P = 0.0027). Furthermore, univariate and multivariate analyses of overall survival showed that NRN1 immunoreactivity was an independent prognostic factor for RCC (P = 0.0012 and 0.036, respectively) (Table 2). We also presented representative IHC images of NRN1 with disease stages (I-IV) in neoplastic and paired adjacent non-neoplastic tissues in Supplementary Figure 1. These NRN1 IHC images and the association study of Table 1 may indicate that there is a positive tendency for the correlation between NRN1 immunoreactivity and stages. Grades were not basically associated with NRN1 immunoreactivity as shown in Table 1. In addition, high NRN1 immunoreactivities were found in neoplastic areas at stages III and IV compared with their paired corresponding non-neoplastic areas. Of 100 paired analyses, high immunoreactivities were detected in 21 neoplastic areas whereas not in non-neoplastic areas (P < 1.0e-4 by McNemar’s test). In RNA-seq dataset of TCGA RCC cohort (n = 845), patients with high NRN1 mRNA levels had shorter overall survival rate than those with low NRN1 levels (expression level range: 0.1-204.2 FPKM, expression median level: 2.9, expression cut off level 6.6 FPKM, P = 3.4e-4) (Figure 1C). NRN1 mRNA levels in stages III and IV RCC tumors significantly higher in those in stages I and II RCC tumors (P = 5.4e-6) (Supplementary Figure 2A). Moreover, we examined RCC-subtype dependent NRN1 expressions and prognostic values based on the TCGA datasets for ccRCC (KIRC), papillary RCC (KIRP), and chromophobe RCC (KICH) through the Human Protein Atlas website. As shown in Supplementary Figure 3, KIRC tissues expressed higher levels of NRN1 compared with KIRP and KICH tissues. In addition, high NRN1 expression was significantly associated with poor survival in patients with KIRC and KIRP. These results suggest that NRN1 may play an oncogenic role in ccRCC and renal papillary cell carcinoma at least.

**CXCR4 Is a Stemness-Related Gene Co-Expressed With NRN1 in RCC and Its Expression Is a Prognostic Biomarker in RCC**

We next explored genes co-expressed with NRN1 in ccRCC tumors. Because we previously identified that NRN1 was abundantly expressed in patient-derived testicular germ cell tumor spheroid cultures with the enrichment of cancer stemness characteristics, we particularly examined the co-expression of NRN1 with stemness-related genes in RCC. In TCGA PanCancer Atlas RNA-seq dataset of ccRCC cohort (n = 352), we found that C-X-C chemokine receptor type 4 (CXCR4) is a stemness-related gene whose expression is substantially correlated with NRN1 expression (Spearman’s correlation coefficient = 0.263, q-value 9.83e-6). In terms of other prototypic stemness-related genes such as CD44, OCT3/4, and SOX2, Spearman’s correlation coefficients for co-expression were <0.2. Based on the
TCGA PanCancer Atlas RNA-seq dataset of ccRCC cohort, we extracted 1,974 and 3,265 genes co-expressed with NRN1 and CXCR4, respectively, with Spearman’s correlation coefficient ≥0.2 and determined 941 common genes as the overlap of genes co-expressed with both NRN1 and CXCR4 (Supplementary Figure 4). Among the top 10 identified Gene Ontology (GO) Terms using The Database for Annotation, Visualization and Integrated Discovery (DAVID), pathways related to such as extracellular matrix, collagen catabolic process, collagen fibril organization, angiogenesis, and cell adhesion were identified.

We next examined the correlation of CXCR4 expression with RCC patient prognosis in the 100 ccRCC tumor specimens as described above. Prior to immunohistochemical study, the CXCR4 antibody was used in Western blotting where CXCR4 protein levels were decreased and increased by NRN1 silencing and overexpression in RCC-PDC1 cells, respectively (Supplementary Figures 5A, B). We determined 25 of 100 tumor tissues showed high CXCR4 IHC staining in the cytoplasm of cancer cells (Supplementary Figure 5C). Kaplan-Meier analysis of the 100 cases showed that patients with high CXCR4 IHC staining showed significant shorter overall survival rate than those with low CXCR4 IHC staining (P = 3.0e-5) (Supplementary Figure 5D). In RNA-seq dataset of TCGA RCC cohort (n = 845), patients with high CXCR4 mRNA levels had shorter overall survival rate than those with low CXCR4 levels (expression level range: 2.1–372.0 FPKM, expression median level: 61.8, expression cut off level: 99.5 FPKM, P = 1.1e-5) (Supplementary Figure 5E). Similar to NRN1 expression, CXCR4 mRNA levels in stages III and IV RCC tumors significantly higher in those in stages I and II RCC tumors (P = 1.3e-6) (Supplementary Figure 2B).

NRN1 and CXCR4 Expression in Patient-Derived RCC Models

To investigate the roles of NRN1 and CXCR4 in RCC, we established RCC-PDC spheroid cultures from 2 distinct patients with ccRCC, RCC-PDC1 and RCC-PDC2. Transplantation of RCC-PDC1 and RCC-PDC2 into the flanks of immunocompromised male NOG mice could successfully generate PDC-originated xenograft (PDCX) tumors. Hematoxylin and eosin (HE) staining and NRN1 immunostaining showed that RCC-PDC1 spheroid culture and its PDCX tumors recapitulated the morphological and immunohistological features of ccRCC (Figure 2). In the case of RCC-PDC2, the original patient tumor contained a tissue portion of ccRCC cells with eosinophilic cytoplasm and high NRN1/CXCR4 IHC staining, which feature was recapitulated in the established PDC spheroid culture and its PDCX tumor (Figure 2).

NRN1 and CXCR4 Contribute to RCC-PDC Viability

We next questioned whether NRN1 and CXCR4 play roles in RCC cell proliferation. We evaluated the effect of NRN1
TABLE 2 | Univariate and multivariate analyses of overall survival in 100 clear cell RCC patients.

| Variables                                      | Univariate |          | Multivariate |          |
|------------------------------------------------|------------|----------|--------------|----------|
|                                                 | P value    | Relative risk (95% CI) | P value    | Relative risk (95% CI) |
| Corrected serum calcium (mg dl⁻¹)               | 5.0e⁻⁶†    | 2.6 (0.57-12) | 0.22        | 22 (2.5-201) |
| (≥ 10 mg dl⁻¹/ < 10 mg dl⁻¹)                     | 1.1e⁻⁴†    | 5.1 (1.3-20)  | 0.0021      | 4.2 (1.1-16)  |
| LDH (≥ 1.5 × ULN/ < 1.5 × ULN)                  | 1.6e⁻⁴†    | 1.6 (0.42-6.1) | 0.96        | 0.50 (0.094-2.6) |
| Pathological T factor (pT)                      | 0.0012†    | 0.036     | 0.066        | 0.83     |
| (pT3-4/pT1-2)                                   | 0.0022†    | 0.87      | 0.079†       | 0.86     (14-5.3) |
| Hb (≥ LLN/ < LLN)                               | 0.021†     | 1.0e⁻⁴    | 0.036       | 1.0e⁻⁴    |
| CRP (≥ 0.20 mg dl⁻¹/ < 0.20 mg dl⁻¹)            | 0.066†     | 0.22      | 0.96        | 2.6 (0.57-12) |
| Lymph node metastasis (positive/negative)       | 0.079†     | 0.87      | 0.036       | 1.6 (0.42-6.1) |
| Age (≥ 67/ < 67)                                | 0.37       | 1.0e⁻⁴    | 0.036       | 1.6 (0.42-6.1) |
| Grade (3,4/1,2)                                 | 0.66       | 1.0e⁻⁴    | 0.036       | 1.6 (0.42-6.1) |
| Gender (male/female)                            | 0.82       | 1.0e⁻⁴    | 0.036       | 1.6 (0.42-6.1) |

Statistical analysis was evaluated by a proportional hazard model (Cox).

P value < 0.05 and 0.05 ≤ P value < 0.10 were significant (in bold) and borderline significant (in italics), respectively.

95% CI, 95% confidence interval.

†Significant (P < 0.05) and borderline significant (0.05 ≤ P value < 0.10) values were examined in the multivariate analyses in this study.

*Corrected serum calcium (mg dl⁻¹) = measured total calcium (mg dl⁻¹) + 0.8 (4.0 - serum albumin (g dl⁻¹).

ULN of LDH is 245 U l⁻¹.

LLN of Hb are 13.5 and 11.3 g/dL for male and female, respectively.

Hb, hemoglobin; LLN, lower limit of normal; ULN, upper limit of normal; LDH, lactate dehydrogenase; CRP, C-reactive protein.

knockdown on RCC-PDC viability by transfecting NRN1-specific siRNAs siNRN1 #1 and #2. These siRNAs significantly repressed NRN1 expression levels in PDCs compared with the control siRNA (siControl) (Figures 3A, C), and impaired the viabilities of RCC-PDC1 and -PDC2 spheroid cultures (Figures 3B, D). Conversely, NRN1 overexpression in PDCs significantly upregulated NRN1 mRNA levels compared with transfection with control vector (Figures 3E, G) and increased the viabilities of RCC-PDC spheroid cultures (Figures 3F, H).

We examined whether NRN1 expression modulates CXCR4 expression in RCC-PDC spheroid cultures. NRN1 silencing (Figures 3I, J) and overexpression (Figures 3K, L) significantly downregulated and upregulated CXCR4 expression, respectively. Moreover, CXCR4-specific siRNAs (siCXCR4 #1 and #2) significantly repressed CXCR4 expression levels compared with siControl (Figures 3M, O) and impaired the viabilities of RCC-PDC spheroid cultures (Figures 3N, P). Additionally, we evaluated the correlation between NRN1 and CXCR4 immunoreactivities in our 100 ccRCC cases. Of 25 high CXCR4 immunoreactivity cases, 12 (48%) and 13 (52%) had high and low NRN1 immunoreactivities, respectively, and of 75 low CXCR4 immunoreactivity cases, 9 (12%) and 66 (88%) had high and low NRN1 immunoreactivities, respectively (P = 1.0e⁻⁴ by Chi-square test).

As a potential NRN1-activated transcriptional factor, nuclear factor of activated T-cells (NFAT) c4 may activate CXCR4 transcription in ccRCC based on previous literature describing that NRN1 activates NFATc4 via binding to insulin receptor in neuronal cells (19), and that NFATc4-binding on the CXCR4 promoter increases CXCR4 expression in 3D spheroid culture of ovarian cancer cells (20). In this context, it is notable that NFATC4 mRNA expression is substantially correlated with NRN1 expression in TCGA PanCancer Atlas RNA-seq dataset of ccRCC cohort (Spearman’s correlation coefficient = 0.333, q-value 1.38e⁻¹⁰). Moreover, qRT-PCR experiment demonstrated that NRN1 knockdown decreased NFATC4 mRNA levels in both RCC-PDC1 and 2, supporting the notion of intermediate function of NFATC4 between NRN1 and CXCR4 (Supplementary Figure 6).

NRN1 Silencing Is a Potential Therapeutic Strategy for RCC Tumor

We further questioned whether NRN1-specific siRNAs can repress in vivo RCC tumor growth. In RCC-PDC1-derived xenograft models in nude mice, siNRN1 #1 or siControl was directly injected into the subcutaneous tumors twice a week when the tumor volume exceeded 150 mm³. siNRN1 injection significantly repressed the growth of RCC-PDC1-derived tumors compared with siControl injection (Figures 4A, B), while body weights of mice were not substantially different between the 2 groups (Figure 4C). In the dissected tumors of siNRN1 #1-treated mice, NRN1 and CXCR4 immunoreactivities were negligible and NRN1 and CXCR4 mRNA levels were...
significantly decreased compared with those of siControl-treated mice (Figures 4D–F). In summary, NRN1 plays an oncogenic role in RCC in cooperation with CXCR4 (Figure 4G).

**DISCUSSION**

In the present study, we identified that NRN1 is as a poor prognostic biomarker for RCC. In PDC/PDCX models, we showed that NRN1 promotes in vitro and in vivo RCC proliferation, and NRN1 silencing downregulates CXCR4, a gene co-expressed with NRN1, that is also a prognostic and CSC marker in RCC. Our data suggest that NRN1 exhibits a tumor-promoting effect in RCC in collaboration with CXCR4. We have previously showed that NRN1 is abundantly expressed in testicular germ cell tumor PDC spheroid culture, and NRN1 expression is transcriptionally regulated by hypoxia inducible factor 1α (HIF1α) (12). Intriguingly, hypoxia-induced expression of NRN1 was also shown in melanoma cells, and soluble NRN1 induced to form vascular mimicry by melanoma cells (21). In ccRCC tumors, the loss-of-function mutations of von Hippel–Lindau tumor suppressor (VHL), an E3 ubiquitin
ligase that targets HIF1α under normoxic conditions, are usually responsible for hypoxia response activation (22, 23). Hypoxic conditions in RCC can also be modulated by obesity, which often leads to the accumulation of peritumoral adipose tissue (24). It is notable that CXCR4 is a prototypic HIF1α target gene in RCC (22), and also identified as a CSC marker in RCC (7).

Overall, both NRN1 and CXCR4 expression can be modulated by hypoxic environments in RCC, while a molecular mechanism how NRN1 modulates CXCR4 expression remains to be clarified. Because NRN1 activates transcription factor nuclear factor of activated T-cells (NFAT) c4 via the binding NRN1 to insulin receptor and the activation of calcium signaling-calmodulin-
calcineurin axis in neuronal cells (19), NRN1 may also activate CXCR4 transcription by modulating some transcriptional machinery in RCC cells.

In terms of NRN1 functions, previous gain- and loss-of-function studies have indicated that NRN1 stimulates anchorage-independent growth and tumorigenesis, suggesting potential NRN1-mediated transformation ability (25). In addition, NRN1 has been reported to have a protective effect on cortical progenitor cells in the fetal brain by preventing caspase-dependent apoptosis (26). NRN1 has also been reported to be involved in cell-cell and cell-ECM adhesion (27). Notably, our pathway analysis revealed that ECM-associated pathways were enriched among genes correlated with both NRN1 and CXCR4 expression in TCGA ccRCC.
NRN1 is stimulated by Ca\(^{2+}\) in promoting role (30, 31). Interestingly, in mouse neuronal cells, potassium channel activation (19, 32). Besides, Ca\(^{2+}\) signaling/influx in RCC cells has been shown to play a tumor promoting role (30, 31). Interestingly, in mouse neuronal cells, NRN1 is stimulated by Ca\(^{2+}\) influx and also upregulates intracellular Ca\(^{2+}\) concentration and signaling through potassium channel activation (19, 32). Besides, Ca\(^{2+}\) signaling is associated with CXCR4 regulation. Ca\(^{2+}\)-induced CXCR4 expression is found in bone marrow cells in mice (33) and CXCR4-mediated intracellular Ca\(^{2+}\) upregulation is implicated in cell migration in breast cancer and oral squamous cell carcinoma (34, 35). Therefore, NRN1 and CXCR4 may be associated with perturbation of calcium regulation in RCC.

NRN1 immunoreactivity was also correlated with serum CRP levels in our study. NRN1 has been reported as an angiogenic factor in tumors (36), and CRP, a marker of inflammation, is known as an informative predictor for patient survival in RCC (37). In addition, CXCR4 plays an important role in inflammation with its ligand CXCL12 and associates with pathological processes such as tumor proliferation, angiogenesis, and metastasis (38). These findings suggest that NRN1 and CXCR4 may coordinately contribute to tumor inflammation and angiogenesis (39).

PDC/PDX models are useful tools for investigating molecular mechanisms that can be applied to personalized medicine and drug screening. In particular, advanced ccRCC is usually treated by targeted therapies or combination treatment including VEGF-TKIs, mTOR inhibitors, and immunotherapy, so the PDC/PDX models may exert advantages to investigate drug sensitivity and resistance against such treatments. Considering that NRN1 is an angiogenic factor in literature, we could speculate that NRN1 may have relevance in VEGF-TKI resistance. We thus consider that the generation of NRN1-overexpressed or -silenced PDC models from both ccRCC and non-ccRCC will address the point whether NRN1 contributes to the mechanism of VEGF-TKI resistance.

We used patient-derived ccRCC cells in the present study as NRN1 is abundantly expressed in these models, although we understand the usefulness of cell line-based study as the molecular mechanisms of established cell lines have been well characterized compared with our patient-derived models. While we successfully showed the oncogenic relevance of DPP4 in both patient-derived RCC spheroid cultures and RCC cell lines (10), RCC cell line such as 786-O may also be useful to characterize the biological function and potential regulation roles of NRN1.

Taken together, the present study suggests that NRN1 can be a potential diagnostic and therapeutic target in RCC.

**CONCLUSIONS**

NRN1 regulates RCC proliferation in cooperation with CXCR4. Patient-derived cancer models would be useful for elucidating novel therapeutic targets in RCC.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Institutional Review Board of the Saitama Medical Center, Saitama Medical University. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Animal Care and Use Committee of Saitama Medical University.

**AUTHOR CONTRIBUTIONS**

SKam, KH, and SI: study concepts and design. SKam, TS, WS, SKit, and KI: data acquisition. SKam, TS, and KI: data analysis and interpretation. SKam, KH, and SI: manuscript preparation. KH, TS, TI, SKaw, and SI: manuscript editing/review. All authors read and approved the final manuscript.

**FUNDING**

This study was supported by the Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (20K21667, 20H03734, 20K21636, and 21H02981) and by the Grant for Cancer Research from the Vehicle Racing Commemorative Foundation.

**ACKNOWLEDGMENTS**

We thank Drs. T. Namekawa, Y. Okada, A. Yano, H. Takeshita, M. Kagawa, and S. Aoki for their technical support.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.758503/full#supplementary-material
REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics 2018. CA Cancer J Clin (2018) 68:7–30. doi: 10.3322/caac.21442

2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68:394–424. doi: 10.3322/caac.21492

3. Ghatalia P, Zibelman M, Geynisman DM, Plimack ER. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma. Curr Treat Options Oncol (2017) 18:7. doi: 10.1007/s11864-017-0458-0

4. Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, et al. Checkpoint Inhibitors: A Gene Induced by Neural Activity and Neurotrophins That Promotes Incidence and Prognostic Significance. Acta Pharmacol Sin (2018) 39:1414–20. doi: 10.1038/aps.2017.197–8

5. Fahn HJ, Lee YH, Chen JK, Huang JK, Chen KK, Grebe SK, Anastasiadis PZ, et al. Neuronal Pentraxin 2 Supports Clear Cell Renal Cell Carcinoma by Activating the AMPA-Selective Glutamate Receptor-4. Proc Natl Acad Sci USA (2019) 116:14818–23. doi: 10.1073/pnas.1907202116

6. Le Jan S, Le Meur N, Cazes A, Philippe J, Le Cunff M, Lefer I, et al. Characterization of the Expression of the Hypoxia-Induced Genes Neuritin, TXNIP and IGFBP3 in Cancer. FEBS Lett (2006) 580:3395–400. doi: 10.1016/j.febslet.2005.05.011

7. Japanese Urological Association, Japanese Society of Pathology, and Japan Radiological Society. General Rules for Clinical and Pathological Studies on Renal Cell Carcinoma. 4th ed. Tokyo: Kanehara-shuppan (2011).

8. Kanda Y. Investigation of the Freely Available Easy-to-Use Software “Eir” for Medical Statistics. Bone Marrow Transplant (2013) 48:452–8. doi: 10.1038/bmt.2012.244

9. Yao JJ, Zhao QR, Liu DD, Chow CW, Mei YA. Neuritin Up-Regulates Kv4.2α-Subunit of Pottasium Channel Expression and Affects Neuronal Excitability by Regulating the Calcium-calcineurin-NFATc4 Signaling Pathway. J Biol Chem (2016) 291:17369–81. doi: 10.1074/jbc.m115.708883

10. Huang K, Kiefer C, Kamal A. Novel Role for NFAT3 in ERK-Mediated Regulation of CXC4R. PloS One (2014) 9:e115249. doi: 10.1371/journal.pone.0115249

11. Bosserhoff AK, Schneider N, Ellmann L, Heinzerling L, Kuphal S. The Neurotrophin Neuritin (Cpg15) Is Involved in Melanoma Migration, Attachment Independence Growth, and Vascular Mimicry. Oncotarget (2017) 8:1117–31. doi: 10.18632/oncotarget.13585

12. Staller P, Sultikova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine Receptor CXC4R Downregulated by Von Hippel-Lindau Tumour Suppressor pVHL. Nature (2003) 425:307–11. doi: 10.1038/nature01874

13. Myszczyszyn A, Czarneczak AM, Matak D, Szymanski L, Franz Kornakiewicz. The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis. Stem Cell Rev (2015) 11:919–43. doi: 10.1007/s12015-015-9611-y

14. Turco F, Tucci M, Di Stefano RF, Samuely A, Bungaro M, Audioso M, et al. Renal Cell Carcinoma (RCC): Fatter Is Better? A Review on the Role of Obesity in RCC. Endocr Relat Cancer (2021) 28:R207–16. doi: 10.1038/ERIC–20-0457

15. Naeve GS, Ramakrishnan M, Kramer R, Hevroni D, Citri Y, Theill LE. Neuritin: A Gene Induced by Neural Activity and Neurotrophins That Promotes Incidence and Prognostic Significance. Acta Pharmacol Sin (2018) 39:1414–20. doi: 10.1038/aps.2017.197

16. Fahn HJ, Lee YH, Chen JK, Huang JK, Chen KK, Chang LS. The Incidence and Prognostic Significance of Humoral Hypercalcemia in Renal Cell Carcinoma. J Urol (1991) 145:248–50. doi: 10.1016/s0022-5347(17)38305-2

17. Papworth K, Granqvist K, Liang R, Rasmussen T, Parathyroid Hormone-Related Protein and Serum Calcium in Patients With Renal Cell Carcinoma. Tumour Biol (2005) 26:201–6. doi: 10.1159/000068953

18. Von Roemeling CA, Radisky DC, Marlow LA, Cooper SJ, Grebe SK, Anastasiadis PZ, et al. Neuronal Pentraxin 2 Supports Clear Cell Renal Carcinoma by Activating the AMPA-Selective Glutamate Receptor-4. Cancer Res (2014) 74:4796–810. doi: 10.1158/0008-5472.can-14-0210

19. Kim JH, Hwang KH, Eom M, Kim M, Park YE, Jeong Y, et al. WNK1 Promotes Renal Tumor Progression by Activating TRPC6-NFAT Pathway. FASEB J (2019) 33:8388–99. doi: 10.1096/fj.20180219nr

20. Fujino T, Lee WC, Nedihi E. Regulation of Cpg15 by Signaling Pathways That Mediate Trastuzumab Resistance. Mol Cell Neurosci (2003) 24:538–54. doi: 10.1016/s1097-4547(03)00230-0

21. Wu Q, Shao H, Darwin ED, Li J, Li Y, Yang B, et al. Extracellular Calcium Increases CXC4R Expression on Bone Marrow-Derived Cells and Enhances Pro-Angiogenesis Therapy. J Cell Mol Med (2009) 13:3764–73. doi: 10.1111/j.1582-4934.2009.00961.x

22. Del Barrio IDM, Wilkins GC, Meeson A, Ali S, Kirby JA. Breast Cancer: An Examination of the Potential of ACKR3 to Modify the Response of CXC4R to CXCL12. Int J Mol Sci (2018) 19:3591. doi: 10.3390/ijms19113592

23. Uchida D, Onoue T, Kuribayashi N, Tomizuka Y, Tamatani T, Nagai H, et al. Characterization of the Expression of the Hypoxia-Induced Genes Neuritin, TXNIP and IGFBP3 in Cancer. FEBS Lett (2006) 580:3395–400. doi: 10.1016/j.febslet.2005.05.011

24. Kamada S, Namekawa T, Ikeda K, Suzuki T, Kagawa M, Takeshita H, et al. NRN1 in Renal Cell Carcinoma: Results From the CABOREAL Early Access Program. Eur J Cancer (2021) 142:102–11. doi: 10.1016/j.ejca.2020.09.030

25. Clevers H. The Cancer Stem Cell: Premises, Promises and Challenges. Nat Med (2011) 17:313–9. doi: 10.1038/nm.2304

26. Kamada S, Namekawa T, Ikeda K, Suzuki T, Kagawa M, Takeshita H, et al. Functional Inhibition of Cancer Stemness-Related Protein DP44 Rescues Tyrosine Kinase Inhibitor Resistance in Renal Cell Carcinoma. Oncogene (2021) 40:389–93. doi: 10.1038/s41388-021-01822-5

27. Fendler A, Bauer D, Busch J, Jung K, Wulf-Goldenberg A, Kunz S, et al. Inhibiting WNT and NOTCH in Renal Cancer Stem Cells and the Implications for Human Patients. Nat Commun (2020) 11:929. doi: 10.1038/s41467-020-14700-7
39. Zhao Y, Adjei AA. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. Oncologist (2015) 20:660–73. doi: 10.1634/theoncologist.2014-0465

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Kamada, Ikeda, Suzuki, Sato, Kitayama, Kawakami, Ichikawa, Horie and Inoue. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.